Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
← catalyst calendarNCT06180278 · readout in 677 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
32actual
Sites
11
Countries
China, Czechia, Hungary +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-02 | actual | When the study began enrolling |
| Primary completion | 2028-06-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-26 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neuromyelitis Optica Spectrum Disorder
Interventions
- Other: Blood tests
- Drug: Inebilizumab — also filed as UPLIZNA
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in serum Ig levels (total Ig, IgG, IgM, IgA, IgE) over time
measured Up to 42 months
Change from baseline in peripheral CD20+ B-cell counts over time
measured Up to 42 months
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed